Cargando…

N6-methyladenosine RNA methylation regulators contribute to the progression of prostate cancer

Prostate cancer (PCa) is one of the most common epithelial malignant tumors and the fifth leading cause of cancer death in men. An increasing number of studies have demonstrated that N6-methyladenosine (m(6)A) plays a crucial role in tumorigenesis and tumor development. However, little is known abou...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Qunying, Xie, Xing, Huang, Yiming, Meng, Shanshan, Li, Youcheng, Wang, Huifeng, Hu, Yanling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778550/
https://www.ncbi.nlm.nih.gov/pubmed/33403026
http://dx.doi.org/10.7150/jca.46379
_version_ 1783631150690861056
author Wu, Qunying
Xie, Xing
Huang, Yiming
Meng, Shanshan
Li, Youcheng
Wang, Huifeng
Hu, Yanling
author_facet Wu, Qunying
Xie, Xing
Huang, Yiming
Meng, Shanshan
Li, Youcheng
Wang, Huifeng
Hu, Yanling
author_sort Wu, Qunying
collection PubMed
description Prostate cancer (PCa) is one of the most common epithelial malignant tumors and the fifth leading cause of cancer death in men. An increasing number of studies have demonstrated that N6-methyladenosine (m(6)A) plays a crucial role in tumorigenesis and tumor development. However, little is known about the role and levels of common m(6)A regulators and m(6)A levels in PCa. In this study, we analyzed the characteristic expression of m(6)A regulators in PCa and castration-resistant prostate cancer (CRPC). UALCAN and cBioPortal were used to estimate the clinical value and genetic alterations of m(6)A regulators, respectively. The correlation between m(6)A regulators and androgen receptor (AR) was assessed using Gene Expression Profiling Interactive Analysis (GEPIA) by Pearson correlation statistics. Total m(6)A levels were detected in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice and PCa cell lines. Results showed that the expression of methyltransferase-like 3 (METTL3) and YTH domain family members, namely, YTHDC2, YTHDF1, and YTHDF2 were generally upregulated in PCa, whereas those of fat mass and obesity-associated protein (FTO), AlkB homolog 5 (ALKBH5), and methyltransferase-like 14 (METTL14) were downregulated. The expression of METTL3, METTL14, Wilms' tumor 1-associating protein (WTAP), YTHDC2, YTHDF1, and YTHDF2 were remarkably higher in CRPC with lymph node metastasis than that in CRPC with bone metastasis, whereas ALKBH5, FTO, and YTHDF3 significantly decreased in CRPC with lymph node metastasis tissues. YTHDF1, YTHDF2, and YTHDC2 were positively correlated with the Gleason grades of PCa, and METTL14, FTO, and ALKBH5 were negatively associated with the Gleason classification. M(6)A regulators were positively correlated with AR. Patients with a genomic alteration of m(6)A were associated with poor disease-free survival (DFS). The total m(6)A levels in TRAMP mice increased dramatically compared with those in tumor-free mice, and m(6)A levels in LNCaP cell lines were higher than DU145 and PC3 cell lines. In summary, METTL3, METTL14, ALKBH5, FTO, YTHDC2, YTHDF1, and YTHDF2 were abnormally expressed in PCa and related to Gleason classification. Changes in m(6)A levels maybe contributed to the development and progression of PCa.
format Online
Article
Text
id pubmed-7778550
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-77785502021-01-04 N6-methyladenosine RNA methylation regulators contribute to the progression of prostate cancer Wu, Qunying Xie, Xing Huang, Yiming Meng, Shanshan Li, Youcheng Wang, Huifeng Hu, Yanling J Cancer Research Paper Prostate cancer (PCa) is one of the most common epithelial malignant tumors and the fifth leading cause of cancer death in men. An increasing number of studies have demonstrated that N6-methyladenosine (m(6)A) plays a crucial role in tumorigenesis and tumor development. However, little is known about the role and levels of common m(6)A regulators and m(6)A levels in PCa. In this study, we analyzed the characteristic expression of m(6)A regulators in PCa and castration-resistant prostate cancer (CRPC). UALCAN and cBioPortal were used to estimate the clinical value and genetic alterations of m(6)A regulators, respectively. The correlation between m(6)A regulators and androgen receptor (AR) was assessed using Gene Expression Profiling Interactive Analysis (GEPIA) by Pearson correlation statistics. Total m(6)A levels were detected in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice and PCa cell lines. Results showed that the expression of methyltransferase-like 3 (METTL3) and YTH domain family members, namely, YTHDC2, YTHDF1, and YTHDF2 were generally upregulated in PCa, whereas those of fat mass and obesity-associated protein (FTO), AlkB homolog 5 (ALKBH5), and methyltransferase-like 14 (METTL14) were downregulated. The expression of METTL3, METTL14, Wilms' tumor 1-associating protein (WTAP), YTHDC2, YTHDF1, and YTHDF2 were remarkably higher in CRPC with lymph node metastasis than that in CRPC with bone metastasis, whereas ALKBH5, FTO, and YTHDF3 significantly decreased in CRPC with lymph node metastasis tissues. YTHDF1, YTHDF2, and YTHDC2 were positively correlated with the Gleason grades of PCa, and METTL14, FTO, and ALKBH5 were negatively associated with the Gleason classification. M(6)A regulators were positively correlated with AR. Patients with a genomic alteration of m(6)A were associated with poor disease-free survival (DFS). The total m(6)A levels in TRAMP mice increased dramatically compared with those in tumor-free mice, and m(6)A levels in LNCaP cell lines were higher than DU145 and PC3 cell lines. In summary, METTL3, METTL14, ALKBH5, FTO, YTHDC2, YTHDF1, and YTHDF2 were abnormally expressed in PCa and related to Gleason classification. Changes in m(6)A levels maybe contributed to the development and progression of PCa. Ivyspring International Publisher 2021-01-01 /pmc/articles/PMC7778550/ /pubmed/33403026 http://dx.doi.org/10.7150/jca.46379 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Wu, Qunying
Xie, Xing
Huang, Yiming
Meng, Shanshan
Li, Youcheng
Wang, Huifeng
Hu, Yanling
N6-methyladenosine RNA methylation regulators contribute to the progression of prostate cancer
title N6-methyladenosine RNA methylation regulators contribute to the progression of prostate cancer
title_full N6-methyladenosine RNA methylation regulators contribute to the progression of prostate cancer
title_fullStr N6-methyladenosine RNA methylation regulators contribute to the progression of prostate cancer
title_full_unstemmed N6-methyladenosine RNA methylation regulators contribute to the progression of prostate cancer
title_short N6-methyladenosine RNA methylation regulators contribute to the progression of prostate cancer
title_sort n6-methyladenosine rna methylation regulators contribute to the progression of prostate cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778550/
https://www.ncbi.nlm.nih.gov/pubmed/33403026
http://dx.doi.org/10.7150/jca.46379
work_keys_str_mv AT wuqunying n6methyladenosinernamethylationregulatorscontributetotheprogressionofprostatecancer
AT xiexing n6methyladenosinernamethylationregulatorscontributetotheprogressionofprostatecancer
AT huangyiming n6methyladenosinernamethylationregulatorscontributetotheprogressionofprostatecancer
AT mengshanshan n6methyladenosinernamethylationregulatorscontributetotheprogressionofprostatecancer
AT liyoucheng n6methyladenosinernamethylationregulatorscontributetotheprogressionofprostatecancer
AT wanghuifeng n6methyladenosinernamethylationregulatorscontributetotheprogressionofprostatecancer
AT huyanling n6methyladenosinernamethylationregulatorscontributetotheprogressionofprostatecancer